Ticker > Company >

Syncom Formulations share price

Syncom Formulations (India) Ltd.

NSE: SYNCOMF BSE: 524470 SECTOR: Pharmaceuticals & Drugs  2.75 L   1.31 K   182

16.39
+0.07 (0.43%)
BSE: 16 Oct 04:01 PM

Price Summary

Today's High

₹ 16.7

Today's Low

₹ 16.2

52 Week High

₹ 23.95

52 Week Low

₹ 14.1

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1540.66 Cr.

Enterprise Value

1544.01 Cr.

No. of Shares

94 Cr.

P/E

27.04

P/B

4.33

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  3.78

CASH

0.69 Cr.

DEBT

4.04 Cr.

Promoter Holding

50.57 %

EPS (TTM)

₹  0.61

Sales Growth

79.15%

ROE

15.61 %

ROCE

18.66%

Profit Growth

106.88 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year79.15%
3 Year28.2%
5 Year17.63%

Profit Growth

1 Year106.88%
3 Year35.17%
5 Year27.95%

ROE%

1 Year15.61%
3 Year10.93%
5 Year12.17%

ROCE %

1 Year18.66%
3 Year12.91%
5 Year14.01%

Debt/Equity

0.0119

Price to Cash Flow

66.09

Interest Cover Ratio

77.0506

CFO/PAT (5 Yr. Avg.)

0.297735220072904

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 50.57 0.00
Jun 2025 50.57 0.00
Mar 2025 50.57 0.00
Dec 2024 50.57 0.00
Sep 2024 50.57 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 35.1661428824251% for the Past 3 years.
  • The company has shown a good revenue growth of 28.2014752641914% for the Past 3 years.
  • The company has significantly decreased its debt by 67.6071 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 77.0506.
  • Company’s PEG ratio is 0.253021203071533.
  • The company has an efficient Cash Conversion Cycle of 64.5899 days.
  • Company has a healthy liquidity position with current ratio of 4.4693.
  • The company has a high promoter holding of 50.57%.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 86.83 101.49 127.03 148.46 116.55
Total Expenditure 76.36 89.56 112.43 130.99 100.77
Operating Profit 10.47 11.93 14.6 17.47 15.78
Other Income 1.31 4.18 3.83 6.9 6.02
Interest 0.39 0.16 0.21 0.09 0.24
Depreciation 1.3 1.3 1.31 1.29 1.34
Exceptional Items 0 0 0 0.01 0.04
Profit Before Tax 10.1 14.65 16.9 23.01 20.26
Tax 2.47 3.7 4.11 5.51 4.53
Profit After Tax 7.63 10.95 12.79 17.5 15.73
Adjusted EPS (Rs) 0.08 0.12 0.14 0.19 0.17

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 244.81 219.66 224.64 258.36 462.85
Total Expenditure 206.76 199.63 204.76 230.51 409.34
Operating Profit 38.04 20.04 19.88 27.85 53.51
Other Income 7.14 11.99 14.61 13.1 17.19
Interest 0.48 1.93 3.4 4.45 0.85
Depreciation 4.03 3.95 4.54 4.72 5.19
Exceptional Items 0.03 0.02 0.01 -0.02 0.01
Profit Before Tax 40.7 26.18 26.57 31.76 64.66
Tax 11.53 6.39 6.5 8.14 15.79
Net Profit 29.17 19.79 20.07 23.62 48.87
Adjusted EPS (Rs.) 0.37 0.23 0.21 0.25 0.52

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 79 86.25 94 94 94
Total Reserves 108.59 135.98 162.01 192.45 245.9
Borrowings 0 0 0 0 0
Other N/C liabilities 7.36 7.76 8.66 10 11.81
Current liabilities 96.7 78.26 112.27 97.28 60.38
Total Liabilities 291.65 308.24 376.94 393.73 412.1
Assets
Net Block 44.32 46.61 43.4 72.42 77.57
Capital WIP 0.38 6.2 25.59 0 0
Intangible WIP 0 0 0 0 0
Investments 1.17 1.93 1.87 2.52 3.65
Loans & Advances 1.1 2.25 2.26 1.01 1.2
Other N/C Assets 54.84 111.46 123.06 52.92 59.8
Current Assets 189.84 139.8 180.77 264.87 269.88
Total Assets 291.65 308.24 376.94 393.73 412.1
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 40.67 26.15 26.55 31.78 64.65
Adjustment -2.1 -7.16 -6.12 -3.27 -10.97
Changes in Assets & Liabilities -29.34 3.58 -3.28 -26.87 -15.92
Tax Paid -11.3 -6.25 -6.65 -7.58 -14.45
Operating Cash Flow -2.06 16.33 10.5 -5.94 23.31
Investing Cash Flow -75.35 -27.07 -44.97 83.83 -18.38
Financing Cash Flow 71.96 8.29 35 -15.37 -67.59
Net Cash Flow -5.46 -2.45 0.53 62.52 -62.66

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
promoters 50.57 50.57 50.57 50.57 50.57
ankit bankda 4.99 4.99 4.99 4.99 4.99
ankur vijay bankda 0.01 0.01 0.01 0.01 0.01
asha vijay bankda 4.90 4.90 4.90 4.90 4.90
kedarmal shankarlal bankd... 12.44 12.44 12.44 12.44 12.44
kedarmal shankarlal bankd... 1.12 1.12 1.12 1.12 1.12
paradise vyapar private l... 5.02 5.02 5.02 5.02 5.02
payal ankur bankda 1.25 1.25 1.25 1.25 1.25
rahul bankda 0.02 0.02 0.02 0.02 0.02
strand developers pvt ltd... - - - 3.82 3.82
sulabh rahul bankda 0.99 0.99 0.99 0.99 0.99
vijay bankda huf 1.28 1.28 1.28 1.28 1.28
vijay shankarlal bankda 10.48 10.48 10.48 10.48 10.48
vimla bankda 4.26 4.26 4.26 4.26 4.26
strand developers pvt. lt... 3.82 3.82 3.82 - -
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
investors 49.43 49.43 49.43 49.43 49.43
investor education and pr... 0.22 0.27 - 0.27 0.27
investor education and pr... - - 0.27 - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Syncom Formulations - Quaterly Results 8 Aug, 5:00 PM Syncom Formulations - Quaterly Results 8 Aug, 5:00 PM Syncom Formulations - Quaterly Results 8 Aug, 5:00 PM Syncom Formulations - Quaterly Results 19 May, 5:52 PM Syncom Formulations - Quaterly Results 19 May, 5:52 PM Syncom Formulations - Quaterly Results 19 May, 5:52 PM Syncom Formulations (India) submits newspaper clippings 11 Feb, 5:20 PM Syncom Formulations - Quaterly Results 10 Feb, 4:32 PM Syncom Formulations - Quaterly Results 10 Feb, 4:32 PM Syncom Formulations - Quaterly Results 10 Feb, 4:32 PM Syncom Formulations - Quaterly Results 11 Nov, 5:21 PM Syncom Formulations - Quaterly Results 11 Nov, 5:21 PM Syncom Formulations - Quaterly Results 12 Aug, 4:37 PM Syncom Formulations - Quaterly Results 12 Aug, 4:37 PM Syncom Formulations - Quaterly Results 12 Aug, 4:37 PM Syncom Formulations (India) informs about loss of share certificate 2 Jul, 3:08 PM Syncom Formulations - Quaterly Results 17 May, 6:42 PM Syncom Formulations - Quaterly Results 17 May, 6:42 PM Syncom Formulations (India) submits board meeting intimation 9 May, 2:23 PM Syncom Formulations (India) informs about certificate 5 Apr, 11:10 AM Syncom Formulations (India) informs about disclosure 26 Feb, 5:23 PM Syncom Formulations - Quaterly Results 14 Feb, 5:28 PM Syncom Formulations - Quaterly Results 14 Feb, 5:28 PM Syncom Formulations (India) informs about annual general meeting 29 Aug, 4:33 PM Syncom Formulations - Quaterly Results 14 Aug, 12:00 PM Syncom Formulations - Quaterly Results 14 Aug, 12:00 PM Syncom Formulations - Quaterly Results 29 May, 8:18 PM Syncom Formulations - Quaterly Results 29 May, 8:18 PM Syncom Formulations - Quaterly Results 13 Feb, 8:18 PM Syncom Formulations - Quaterly Results 13 Feb, 8:18 PM Syncom Formulations (India) submits reconciliation of share capital audit report 13 Jan, 4:11 PM Syncom Formulations - Quaterly Results 14 Nov, 9:26 PM Syncom Formulations - Quaterly Results 14 Nov, 9:26 PM Syncom Formulations (India) informs about submission of proceedings of 34th AGM 20 Sep, 4:36 PM Syncom Formulations (India) completes civil structure at Pithampur unit 16 Sep, 11:29 AM Syncom Formulations - Quaterly Results 13 Aug, 8:37 PM Syncom Formulations - Quaterly Results 13 Aug, 8:37 PM Syncom Formulations (India) informs about details of loss of certificate 2 Aug, 1:12 PM Syncom Formulations wins ‘Product Excellence 2022’ award 23 May, 2:07 PM Syncom Formulations (India) informs about press release 20 May, 2:34 PM Syncom Formulations - Quaterly Results 18 May, 9:41 PM Syncom Formulations - Quaterly Results 18 May, 9:41 PM Syncom Formulations (India) informs about receipt of award 21 Apr, 3:24 PM Syncom Formulations - Quaterly Results 14 Feb, 6:43 PM Syncom Formulations - Quaterly Results 14 Feb, 6:43 PM Syncom Formulations - Quaterly Results 13 Nov, 6:40 PM Syncom Formulations (India) informs about disclosure 30 Sep, 10:27 AM Syncom Formulations (India) submits newspaper advertisement 17 Aug, 3:44 PM Syncom Formulations awarded by INDIA 5000 BEST MSME AWARDS 2021 8 Apr, 9:58 AM Syncom Formulations India awarded by IPF Industrial Excellence Awards 2021 16 Jan, 11:11 AM

Syncom Formulations Stock Price Analysis and Quick Research Report. Is Syncom Formulations an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Syncom Formulations. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Syncom Formulations has a PE ratio of 27.1242369245999 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Syncom Formulations has ROA of 12.1295% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Syncom Formulations has a Current ratio of 4.4693.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Syncom Formulations has a ROE of 15.6051%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Syncom Formulations has a Debt to Equity ratio of 0.0119 which means that the company has low proportion of debt in its capital.

  • Sales growth: Syncom Formulations has reported revenue growth of 79.1493% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Syncom Formulations for the current financial year is 11.5599829145253%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Syncom Formulations is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Syncom Formulations is Rs 0.6061. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Syncom Formulations in Ticker for free. Also, one can get the intrinsic value of Syncom Formulations by using Valuation Calculators, which are available with a Finology ONE subscription. 

Syncom Formulations FAQs

Q1. What is Syncom Formulations share price today?
Ans: The current share price of Syncom Formulations is Rs 16.44.

Q2. What is the market capitalisation of Syncom Formulations?
Ans: Syncom Formulations has a market capitalisation of Rs 1545.36 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Syncom Formulations?
Ans: The PE ratio of Syncom Formulations is 27.1242369245999 and the P/B ratio of Syncom Formulations is 4.34541273491396, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Syncom Formulations share?
Ans: The 52-week high share price of Syncom Formulations is Rs 23.87, and the 52-week low share price of Syncom Formulations is Rs 14.1.

Q5. Does Syncom Formulations pay dividends?
Ans: Currently, Syncom Formulations does not pay dividends. Dividend yield of Syncom Formulations is around 0%.

Q6. What are the face value and book value of Syncom Formulations shares?
Ans: The face value of Syncom Formulations shares is Rs 1, while the book value per share of Syncom Formulations is around Rs 3.7833. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Syncom Formulations?
Ans: Syncom Formulations has a total debt of Rs 4.0432 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Syncom Formulations?
Ans: The ROE of Syncom Formulations is 15.6051% and ROCE of Syncom Formulations is 18.6621%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Syncom Formulations a good buy for the long term?
Ans: The Syncom Formulations long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Syncom Formulations undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Syncom Formulations appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Syncom Formulations’s financials?
Ans: You can review Syncom Formulations’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Syncom Formulations
X